124 related articles for article (PubMed ID: 38405900)
1. Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy.
Maurer K; Park CY; Mani S; Borji M; Penter L; Jin Y; Zhang JY; Shin C; Brenner JR; Southard J; Krishna S; Lu W; Lyu H; Abbondanza D; Mangum C; Olsen LR; Neuberg DS; Bachireddy P; Farhi SL; Li S; Livak KJ; Ritz J; Soiffer RJ; Wu CJ; Azizi E
bioRxiv; 2024 Feb; ():. PubMed ID: 38405900
[TBL] [Abstract][Full Text] [Related]
2. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
3. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
Bachireddy P; Hainz U; Rooney M; Pozdnyakova O; Aldridge J; Zhang W; Liao X; Hodi FS; O'Connell K; Haining WN; Goldstein NR; Canning CM; Soiffer RJ; Ritz J; Hacohen N; Alyea EP; Kim HT; Wu CJ
Blood; 2014 Feb; 123(9):1412-21. PubMed ID: 24357730
[TBL] [Abstract][Full Text] [Related]
4. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
[TBL] [Abstract][Full Text] [Related]
5. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
[TBL] [Abstract][Full Text] [Related]
7. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice.
Batatinha H; Diak DM; Niemiro GM; Baker FL; Smith KA; Zúñiga TM; Mylabathula PL; Seckeler MD; Lau B; LaVoy EC; Gustafson MP; Katsanis E; Simpson RJ
Front Immunol; 2023; 14():1067369. PubMed ID: 37077913
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
[TBL] [Abstract][Full Text] [Related]
9. Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.
De Somer L; Sprangers B; Fevery S; Rutgeerts O; Lenaerts C; Boon L; Waer M; Billiau AD
Haematologica; 2011 Mar; 96(3):424-31. PubMed ID: 21109687
[TBL] [Abstract][Full Text] [Related]
10. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
11. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
12. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
13. Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy.
Bachireddy P; Azizi E; Burdziak C; Nguyen VN; Ennis CS; Maurer K; Park CY; Choo ZN; Li S; Gohil SH; Ruthen NG; Ge Z; Keskin DB; Cieri N; Livak KJ; Kim HT; Neuberg DS; Soiffer RJ; Ritz J; Alyea EP; Pe'er D; Wu CJ
Cell Rep; 2021 Nov; 37(6):109992. PubMed ID: 34758319
[TBL] [Abstract][Full Text] [Related]
14. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
15. Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse.
Odak I; Sikora R; Riemann L; Bayir LM; Beck M; Drenker M; Xiao Y; Schneider J; Dammann E; Stadler M; Eder M; Ganser A; Förster R; Koenecke C; Schultze-Florey CR
Front Immunol; 2022; 13():999163. PubMed ID: 36275657
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
17. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
Kogan AA; Lapidus RG; Baer MR; Rassool FV
Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
[TBL] [Abstract][Full Text] [Related]
18. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
19. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.
Castro FA; Palma PV; Morais FR; Voltarelli JC
Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574
[TBL] [Abstract][Full Text] [Related]
20. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
